Accelerating Advanced Therapeutic Modalities Through iPSC And Genome Editing Technologies

With extensive experience in genome editing and induced pluripotent stem cell (iPSC) technologies, this service offers comprehensive support for advancing preclinical autologous, allogeneic, and genomic projects. The process begins with generating disease-relevant cell lines and animal models that provide critical proof-of-concept data. In parallel, customized assay development is conducted to accurately evaluate the biological activity and characteristics of therapeutic candidates.

Beyond model generation, the service includes robust potency, efficacy, and safety assessments designed to meet regulatory expectations and provide confidence in experimental outcomes. These evaluations are crucial steps for moving candidates forward in the drug development pipeline.

Additionally, there is expert consultation available on Chemistry, Manufacturing, and Controls (CMC) aspects, particularly for vector and cell line manufacturing. This ensures scalable, compliant production processes that support clinical and commercial needs.

By leveraging cutting-edge genome editing and stem cell platforms, the service streamlines the screening and preclinical evaluation process. This integrated approach facilitates efficient decision-making and positions therapeutic candidates for successful IND (Investigational New Drug) application filings, accelerating their pathway toward clinical development and eventual patient use.